Ramesh Swaminathan, Global CFO of pharmaceutical company Lupin, warns that Trump tariffs could deny many in the U.S. access ...

Launch details are bound by confidentiality. Lupin Pharmaceuticals, Inc., which was its partner for the abbreviated new drug application approved by the U.S. FDA, will be marketing the product in ...

Lupin has received tentative approval from the Food and Drug Administration for darunavir, cobicistat, emtricitabine, and ...

Lupin's shares recovered after strong Q3 FY25 results, with a net profit of ₹858.9 crore, up 38.8%. North America sales grew ...

Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved needle-free epinephrine product, neffy has the potential ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $501.00. The company’s shares ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo The U.S. Food and Drug Administration ...